Background: this study describes the availability and characteristics of databases in Asian-pacific countries and assesses the feasibility of a distributed network approach in the region. Methods: A web-based survey was conducted among investigators using healthcare databases in the Asia-pacific countries. potential survey participants were identified through the Asian pharmacoepidemiology Network.
W
ith the rapid development of electronic health records and computer technologies in North America and europe, collaborative multi-database projects within or across nations have increased in the past decade. [1] [2] [3] Multinational database studies can offer many advantages, including large sample sizes, cross-country comparisons, and generalizable results. Most importantly, collaboration among countries may also create partnerships that benefit public health. 1, 4 Among european and North American multi-database networks, the distributed network approach has been widely used in the form of common data models. [1] [2] [3] [4] [5] [6] [7] this approach allows individual data partners to maintain operational and physical control over their data. [8] [9] [10] However, the feasibility of a common data model for heterogeneous databases in the Asia-pacific region has not been assessed.
the Asian pharmacoepidemiology Network (AspeN) was initiated in 2008 and now includes Australia, people's republic of China, Hong Kong, india, Japan, Singapore, South Korea, taiwan, and thailand. 11 the availability of claims databases or electronic health records from the AspeN founding countries has been briefly introduced elsewhere, 3 but without data component details and information on the new AspeN countries. We sought to describe the availability and 
METHODS
We used a web-based survey tool to conduct an online survey for investigators possessing or using health databases in the Asia-pacific region.
the survey included 142 questions about the (1) characteristics of the database; (2) access policies and restrictions; (3) population demographic characteristics; (4) data components coding systems used, including diagnoses, procedures, prescriptions, and laboratory data; (5) medical expenditures; and (6) traditional Chinese medicine or complementary medicine.
We identified targeted databases through the AspeN website and recommendations provided by AspeN members. 11 A detailed description of our methods is included in the eAppendix (http://links.lww.com/eDe/A927).
RESULTS
We invited 17 researchers from 13 databases to participate in the survey, and 15 (88%) researchers from 11 (84%) databases responded. A list of participating databases and their characteristics is presented in table 1. Detailed descriptions of participating databases are presented in the eAppendix (http://links.lww.com/eDe/A927).
Unique patient identifiers and demographic characteristics, including sex and birth information, were available in the databases. information on race and ethnicity was available in most electronic health record databases and registries but not in the claims databases. the clinical values for laboratory tests was available in all electronic health records and registries but not in the claims databases. Health expenditure information was available in all the claims databases but not in many electronic health records or registries. Date of death or patient status (i.e., alive or dead) was not available in three claims databases, but could be estimated using eligibility for compulsory national insurance in one claims database. other data components, including information on health care facilities and providers, are shown in table 2.
table 3 details information found in databases about diagnoses, prescriptions, procedures, health expenses, and coding systems.
four databases contained longitudinal dispensing data for traditional Chinese medicine using a domestic coding system. other information about traditional Chinese medicine, such as drugs records, is compiled in a manner consistent with Western medications (table 4) .
DISCUSSION
the survey included 11 databases, including healthcare utilization databases, electronic health records, and registries covering approximately 220 million individual records that are currently available for pharmacoepidemiologic and other clinical researchers. this provides an opportunity to establish a large-scale drug surveillance system for populations in the Asia-pacific region. the NDB is not usually available for purchase. Use of the NDB is restricted to individuals with government or academic affiliations, who must apply for access. Applications for access typically have a low acceptance rate (about 14% and 30% of all applications in 2011 and 2012, respectively). information such as hospital/clinic/pharmacy identifying information, the number of beds in a hospital, and personal identifiers are typically not shared with users, but these data are available in the JMDC. Japan, South Korea, and taiwan, with universal insurance coverage, reimburse most healthcare services from their national budgets, 12 which has led to the establishment of nationwide claims databases for administrative and reimbursement purposes, creating pharmacoepidemiologic data sources representative of the national population. Unlike claims databases, hospital-based electronic health records are usually compiled for clinical purposes, 13 and therefore could provide information to improve the validity of pharmacoepidemiologic studies by improving the specificity of outcome definitions and/or better measurement of confounding factors for adjustment. 
Diagnosis information Domestic coding system × × international coding system iCD-10 iCD-10 iCD-9 iCD-10 iCD-9/iCD-10 iCD-10 iCD-10 iCD-10 iCD-10 iCD-9 iCD-9 Diagnosis start date
the representativeness of hospital-based electronic health records may depend on the proportion of hospitals included in the area. Nationwide systems, such as those in Hong Kong and Singapore, are representative of the entire population, but systems in the people's republic of China and thailand may be less representative, as they represent data for specific regions only. the NHirD, Hong Kong's Clinical Data Analysis and reporting System, Japan's National Database, and South Korea's Health insurance review and Assessment Service are population-based databases, enabling the calculation of the rate of incidence for specific events.
Data privacy and related ethical issues are a major concern when using databases, resulting in a number of policies and restrictions to be established by data custodians. in particular, the privacy of nationwide health databases is paramount because of national security issues. 14, 15 Currently, the data custodians of all Asia-pacific databases included in this study request that researchers obtain approval from an ethics review committee before accessing databases and require encryptions or truncations of specific data. furthermore, we found that the custodians or regulators may partly restrict the availability of data. for example, researchers using taiwan's National Health insurance research Database receive data for 10% or less of the population.
16 the Japan's National Database is usually not available for purchase and may only be shared in some cooperative research. Alternatively, the Japan Medical Data Center Database, a commercial claims database, is less restrictive. 17 Although there are two registry databases available in taiwan that provide important information, linking them to taiwan's National Health insurance research Database is prohibited due to ethical considerations. 16, 18 Due to existing data privacy policies, no individuallevel data from the participating databases could be shared with researchers from other countries, raising questions about how to conduct cross-database studies. A common protocol approach is to have each data partner translate their raw data using an identical study protocol into analytic programs. 19 our findings indicate we will be able to apply this approach to conduct pharmacoepidemiologic studies, including descriptive studies of disease prevalence and incidence, patterns of drugs and health recourse utilization, and associated studies, in the current Asian-pacific database environments. Given that date and cause of death are available through direct records or indirect proxy measures, studies considering mortality would also be possible.
A distributed network approach using a common data model can help avoid inconsistency in analytic processes that arises from different investigators implementing the study protocol differently. this approach executes a systematic program established by a coordinating center on a common data format, which enables quality control of the analyses. this also enables analysts who are knowledgeable about participating health systems to ensure their data are analyzed and interpreted properly. 9, 20 However, researchers could get entangled in another challenge: the conversion of the database to a common data model structure.
9 the common data model could be study-specific or could be a global model applied for most routine pharmacoepidemiologic studies (e.g., the common data model developed by the observational Medical outcomes partnership 21 or Mini-Sentinel 22 ). Given the diversity of language systems among Asia-pacific countries, the communication of a common format and translations of descriptive information stored in databases could be more arduous than in networks where the same language is used. According to our survey, information on drugs and diagnoses are recorded by common coding systems in the majority of participating databases, which would ease the conversion to a common data model. Although NHirD uses iCD-9 codes for diagnoses, a crosswalk from iCD-9 to iCD-10 is almost established. 23 Nevertheless, many databases use domestic coding system for drugs, drug ingredients, strength, and route of administration, which provides a foundation to map these codes to an international coding system (e.g., the Anatomical therapeutic Chemical classification system of World Health organization). We found that the harmonization of health expenditure data would be complicated. in addition to challenges in the conversion of currency and adjustment of the consumer price index, many categories of health expenditures were specific to countries and their health systems. for example, there is no concept of a copayment and deductible in Japan, and in taiwan the dispensing fee is based on the prescription and not at the ingredient level, 16 both of which differ from some of the other countries. Acupuncture is covered by health insurance only for specific diseases in special cases. only a small proportion of acupuncture records are available in the databases.
traditional Chinese medicine, including prescribing herbal medications and acupuncture, is widely used in all of the countries. We found that utilization data were only available in databases in the people's republic of China, Japan, and taiwan. to the best of our knowledge, no international coding system for traditional Chinese medicine currently exists. Consequently, more effort is needed to standard relevant terminologies related to traditional Chinese medicine before establishment of a coding system, including acupuncture, traumatology, manipulative therapies, and Chinese herbal products.
in conclusion, we identified multiple databases with the capability to conduct collaborative studies using a distributed network approach in the Asia-pacific region, which would enable large-scale surveillance to facilitate prompt identification of emerging safety issues. participating health databases are generally comprehensive in population coverage. Some data contents, and many country-specific coding systems and terminologies, have already been converted to international coding systems. However, the harmonization of health expenditure data presents a major obstacle for future investigations in evaluating issues related to medical cost.
